Goldman Sachs
IBRX icon

Goldman Sachs’s ImmunityBio IBRX Stock Holding History

Goldman Sachs’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-69,300
Closed -$438K – 5947
2024
Q2 		$438K Buy
+69,300
New +$457K ﹤0.01% 4901
2024
Q1 		– Sell
-11,500
Closed -$57.7K – 5707
2023
Q4 		$57.7K Buy
+11,500
New +$36.1K ﹤0.01% 5358
2016
Q1 		– Sell
-63,300
Closed -$1.1M – 7176
2015
Q4 		$1.1M Buy
+63,300
New +$939K ﹤0.01% 4204

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's IBRX Position: Q2 2026 in Review

Goldman Sachs reduced its ImmunityBio (IBRX) stake by 0.09% in Q2 2026, selling an estimated $21.2K and leaving 3,234,277 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

Goldman Sachs first reported a position in IBRX in Q4 2015 and has held it in 39 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Goldman Sachs held 3,234,277 shares of ImmunityBio worth $28.3M as of Q2 2026.
  • Goldman Sachs sold 2,801 ImmunityBio shares in Q2 2026, an estimated $21.2K.
  • ImmunityBio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2324 holding.
  • Goldman Sachs first reported a position in ImmunityBio in Q4 2015 and has held it in 39 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.